---
title: "Mustang Bio, Inc. (MBIO.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/MBIO.US.md"
symbol: "MBIO.US"
name: "Mustang Bio, Inc."
industry: "Biotechnology"
datetime: "2026-05-20T09:09:43.901Z"
locales:
  - [en](https://longbridge.com/en/quote/MBIO.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/MBIO.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/MBIO.US.md)
---

# Mustang Bio, Inc. (MBIO.US)

## Company Overview

Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating cell therapies into cures for difficult-to-treat cancers and autoimmune diseases in the United States. The company develops MB-106, a CD20-targeted chimeric antigen receptor (CAR) T cell therapy which is in Phase I clinical trail for non-hodgkin lymphoma, chronic lymphocytic leukemia, and autoimmune diseases; MB-109, a combination MB-101 and MB-108 as a potential treatment for IL13Ra2+ relapsed or refractory glioblastoma and high-grade astrocytoma; MB-101, an IL13Ra2 CAR T cell program completd Phase I for glioblastoma; and MB-108 which is in Phase I for the treatment of herpes simplex virus-1 oncolytic virus C134. It has a license agreement with city of hope national medical center and nationwide children’s hospital. Mustang Bio, Inc.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |
| Website | [www.mustangbio.com](https://www.mustangbio.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: 
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 1970-01-01T00:00:00.000Z

**Overall:  (0.00)**

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -1.79 | 233 | - | - | - |
| PB | 0.57 | 46 | 3.68 | 0.93 | 0.66 |
| Dividend Yield | 0.00% | - | - | - | - |

## Institutional View

### Analyst Rating Distribution

> As of 2024-07-05T04:00:00.000Z

Total Analysts: **1**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Overweight | 1 | 100% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 0.64 |
| Highest Target | undefined |
| Lowest Target | undefined |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/MBIO.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/MBIO.US/norm.md)
- [Related News](https://longbridge.com/en/quote/MBIO.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/MBIO.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**